Erythromycin: Caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

Drug Safety Update

Published 17 December 2020
From: Medicines and Healthcare products Regulatory Agency

Erythromycin has been associated with events secondary to QT interval prolongation such as cardiac arrest and ventricular fibrillation.

Visit Gov.uk website to learn more about Erythromycin , the and the risks and current advice for healthcare professionals.